FOXM1 drives cisplatin resistance in ovarian cancer through STIM1-mediated SOCE and STAT1 activation.

Authors

Tzu-Chien Lin, Meng-Ru Hsieh, Hieu Dac Hanh Nguyen, Sarinporn Visitsattapongse, Wen-Tai Chiu

Published in

Molecular therapy. Oncology. Volume 34. Issue 4. Pages 201347. Dec 17, 2026. Epub Sep 15, 2026.

Abstract

Cisplatin resistance remains a major challenge in ovarian cancer, limiting treatment efficacy and reducing patient survival. While FOXM1 and calcium (Ca²⁺ signaling have been individually implicated in chemoresistance, how transcriptional regulation is linked to Ca²⁺-dependent survival signaling remains poorly understood. To address this gap, we integrated bioinformatic analyses with functional and mechanistic studies in cisplatin-resistant (CR) ovarian cancer models. We found that FOXM1 transcriptionally activate STIM1, thereby enhancing store-operated Ca²⁺ entry (SOCE) and sustaining cytosolic Ca²⁺ levels. Elevated Ca²⁺ influx-activated downstream interferon (IFN)/STAT1 signaling and increased expression of IFN-stimulated genes associated with DNA repair and anti-apoptotic programs. FOXM1 or STIM1 depletion and pharmacological SOCE inhibition attenuated STAT1 activation and restored cisplatin sensitivity, whereas STIM1 re-expression rescued the resistance phenotype following FOXM1 depletion. Using A2780/ACR and IGROV1/ICR ovarian cancer models, together with analyses of TCGA-OV and multiple GEO cohorts, we demonstrate that FOXM1 transcriptionally activates STIM1, thereby enhancing store-operated Ca²⁺ entry and promoting STAT1-dependent IFN signaling. Genetic or pharmacological disruption of this pathway restored cisplatin sensitivity, identifying the FOXM1-STIM1/SOCE-STAT1 axis as a potential therapeutic vulnerability in platinum-resistant ovarian cancer. This study provides mechanistic insight into chemoresistance and highlights avenues for therapeutic intervention in patients with high FOXM1/STIM1 expression.

PMID:
42835994
Bibliographic data and abstract were imported from PubMed on 06 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.